iBio, Inc. (IBIO)

US — Healthcare Sector

Peers: JAGX ONTX GOVX OCGN TNXP ACST DFFN SONN PALI VXRT ADMA BCRX

Automate Your Wheel Strategy on IBIO

With Tiblio's Option Bot, you can configure your own wheel strategy including IBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol IBIO
Rev/Share 0.038
Book/Share 1.154
PB 0.6773
Debt/Equity 0.2575
CurrentRatio 1.1228
ROIC -1.1747

MktCap 12911485.0
FreeCF/Share -1.5989
PFCF -0.8188
PE -0.3672
Debt/Assets 0.1534
DivYield 0
ROE -1.3048

Rating C+
Score 2
Recommendation Sell
P/E Score 1
DCF Score 5
P/B Score 2
D/E Score 2

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

iBio Raises $6.2 Million Through Warrant Inducement Transaction

IBIO
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the “Existing Warrants”), wherein the investors agreed to exercise the Existing Warrants to purchase 5,626,685 shares of common stock at a reduced exercise price of $1.11 per share, resulting in gross proceeds of approximately $6.2 million, before deducting advisory fees and certain other expenses. The Company intends …

image for news iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

IBIO
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

In-Licensing of novel activin E antibody underscores iBio's commitment to delivering meaningful benefits to patients living with obesity and cardiometabolic diseases In-Licensing of novel activin E antibody underscores iBio's commitment to delivering meaningful benefits to patients living with obesity and cardiometabolic diseases

image for news iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

About iBio, Inc. (IBIO)

IPO Date 2008-08-19
Website https://www.ibioinc.com
Industry Biotechnology
CEO Dr. Martin B. Brenner D.V.M., Ph.D.
Employees 16

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.